Procarbazine
Brand names: Matulane ยท Active ingredient: Procarbazine Hydrochloride
In short: MATULANE is indicated for use in combination with other anticancer drugs for the treatment of Stage III or Stage IV Hodgkin Lymphoma.
What is Procarbazine used for?
MATULANE is indicated for use in combination with other anticancer drugs for the treatment of Stage III or Stage IV Hodgkin Lymphoma.
Procarbazine dosage
The recommended dosage of MATULANE for adult and pediatric patients is 100 mg/m2 orally once a day.
Use the patient's actual bodyweight for the recommended dosage, unless the patient is obese or experiencing weight gain due to edema, ascites, or abnormal fluid retention and then use estimated lean body mass.
Individualize the dose and dosing schedule of MATULANE based on the specific regimen administered, response to treatment, and patient risk factors.
Refer to the Prescribing Information for the agents used in combination for dosing information as appropriate.
Monitor complete blood counts (CBCs) prior to initiation of, and as clinically indicated, during treatment with MATULANE . If the following adverse reactions occur, permanently discontinue MATULANE:
Anaphylaxis or other hypersensitivity reactions
If any of the following adverse reactions occur, consider withholding until clinically stable or permanently discontinuing depending on adverse reaction severity:
Grade 4 neutropenia, febrile neutropenia, or signs or symptoms of infection
Grade 4 thrombocytopenia, hemorrhage, or signs of bleeding
Central nervous system signs or symptoms such as paresthesia, neuropathies, or confusion
Stomatitis (ulcerative or persistent pain)
Diarrhea
MATULANE is a hazardous drug. Follow applicable handling and disposal procedures.1
MATULANE can be administered with or without food.
Advise patients to avoid consumption of alcohol during treatment with MATULANE .
How to take Procarbazine โ instructions & advice from the label
Myelosuppression
Inform the patient that MATULANE can cause severe myelosuppression. Advise the patient to immediately report signs or symptoms such as bleeding, easy bruising, symptoms of infection (fever, chills, cough, pain, or burning during urination), fatigue, or shortness of breath to their healthcare provider .
Secondary Malignancies
Advise patients of the increased risk of secondary malignancies .
Risk of Disulfiram-like Reaction Due to Concomitant Use with Alcohol
Inform patients that MATULANE may cause a disulfiram-like reaction when consuming alcohol during treatment. Advise patients to avoid consumption of alcohol during treatment with MATULANE before, after and during therapy with MATULANE .
Embryo-Fetal Toxicity
Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy .
Advise females of reproductive potential to use effective contraception during treatment with MATULANE .
Advise males with female partners of reproductive potential to use effective contraception during treatment with MATULANE . โฆ
Warnings & precautions
Do not take this medicine if: MATULANE is contraindicated in patients with known hypersensitivity or anaphylaxis to the drug or drug components .
Matulane can cause myelosuppression, including severe neutropenia, anemia, and thrombocytopenia.
Obtain complete blood counts prior to initiation of MATULANE and monitor patients during treatment for clinical complications due to myelosuppression. During treatment with MATULANE, monitor hemoglobin, hematocrit, white blood count (WBC) including differential, reticulocytes, and platelets weekly or as clinically necessary.
Myelosuppression often occurs 2 to 8 weeks after the start of MATULANE treatment. If severe myelosuppression occurs, withhold MATULANE until clinically stable, or permanently discontinue depending on severity .
If radiation or a chemotherapeutic agent known to have myelosuppressive activity has been used, an interval of one month or longer without such therapy is recommended before starting treatment with MATULANE. The length of this interval may also be determined by evidence of bone marrow recovery based on successive bone marrow studies.
Secondary malignancies have been reported in patients treated with MATULANE when used in combination with other chemotherapy, including lung cancer, myelodysplastic syndrome, acute myeloid leukemia, and non-Hodgkin Lymphoma. The risks of secondary lung cancer from treatment appear to be increased by tobacco use.
Monitor patients for the development of secondary malignancies during and after treatment with MATULANE.
Increased adverse reactions may occur if Matulane is used in patients with renal or hepatic impairment.
Evaluate renal and hepatic function prior to beginning therapy. Repeat urinalysis, transaminase, alkaline phosphatase and blood urea nitrogen tests at least weekly and as clinically indicated. โฆ
Procarbazine side effects
The following adverse reactions are discussed in more detail elsewhere in the labeling.
Myelosuppression .
Secondary Malignancies .
Risk of Disulfiram-like Reaction Due to Concomitant Use with Alcohol .
Infertility .
The following adverse reactions associated with the use of MATULANE were identified in clinical studies or post-marketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The most common adverse reactions for MATULANE are neutropenia, anemia, thrombocytopenia, nausea, and vomiting.
Other adverse reactions are:
Hematologic: Pancytopenia, eosinophilia, hemolytic anemia
Vascular: Petechiae, purpura, epistaxis, hemoptysis
Hepatobiliary: Hepatic dysfunction, jaundice
Gastrointestinal: Stomatitis, hematemesis, melena, diarrhea, dysphagia, anorexia, abdominal pain, constipation, dry mouth
Neurologic: Coma, convulsions, neuropathy, ataxia, paresthesia, nystagmus, diminished reflexes, falling, foot drop, headache, dizziness, unsteadiness, slurred speech
Cardiovascular: Hypotension, tachycardia, syncope
Ophthalmic: Retinal hemorrhage, papilledema, photophobia, diplopia, inability to focus
Respiratory: Pneumonitis, pleural effusion, cough, hoarseness
Dermatologic: Herpes, dermatitis, pruritus, alopecia, hyperpigmentation, rash, urticaria, flushing
Allergic: Generalized allergic reactions
Genitourinary: โฆ
Drug interactions
Monitor signs and symptoms of neurotoxicity with concomitant use of MATULANE and other central nervous system (CNS) depressing agents. Concomitant use of MATULANE with other CNS depressing agents may result in potentiation of CNS depression with MATULANE.
Avoid monoamine oxidase (MAO) inhibitors and other drugs with MAO inhibition activity within two weeks before, and during treatment with MATULANE. MATULANE exhibits MAO inhibitory activity. Concomitant use of MATULANE with other MAO inhibitors may increase the risk of a hypertensive crisis.
Avoid consumption of alcohol or products containing propylene glycol before, after, and during therapy with MATULANE . Use of MATULANE is associated with a disulfiram-like reaction to alcohol, including abdominal cramps, nausea, vomiting, headaches, and flushing.
Avoid tyramine-containing foods during therapy with MATULANE. Concurrent ingestion of foods rich in tyramine may cause sudden and severe high blood pressure in patients receiving MATULANE.
About this medicine
Procarbazine hydrochloride is an alkylating drug and hydrazine derivative. The chemical name is N-isopropyl-โ-(2-methylhydrazino)-p-toluamide monohydrochloride. It is soluble but unstable in water or aqueous solutions. The molecular weight of procarbazine hydrochloride is 257.76 and the structural formula is:
MATULANE (procarbazine hydrochloride) capsules are for oral use. Each capsule contains approximately 58 mg of procarbazine hydrochloride, equivalent to 50 mg of procarbazine free base. Inactive ingredients in MATULANE are cornstarch, mannitol and talc. Gelatin capsule shells contain titanium dioxide, FD&C Yellow No. 6 and D&C Yellow No. 10.
How it works: The precise mode of cytotoxic action of procarbazine has not been clearly defined. After metabolic activation, procarbazine may inhibit the transmethylation of methyl groups of methionine into transfer RNA (t-RNA). The unavailability of t-RNA prevents protein synthesis, and consequently prevents DNA and RNA synthesis.
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 1aa75a3a-18c9-49e1-91a6-293d0b7da756. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate